India’s pharmaceutical regulatory framework has undergone significant transformation in recent years, with the Central Drugs Standard Control Organisation (CDSCO) and the Pharmacovigilance Programme of India (PvPI) playing increasingly active roles in monitoring drug safety. For international buyers sourcing Indian generic medicines, understanding this safety framework is essential for making informed procurement decisions.
🛡️ How India’s Drug Safety Framework Is Structured
India’s drug safety system operates through two primary pillars: pre-market approval (ensuring a drug is safe and effective before it reaches patients) and post-market surveillance (monitoring safety after approval). The key institutions involved include:
- CDSCO (Central Drugs Standard Control Organisation): The national regulatory body responsible for approving new drugs, conducting quality inspections, and enforcing the Drugs and Cosmetics Act, 1940. CDSCO also publishes Not of Standard Quality (NSQ) alerts when tested batches fail quality standards.
- PvPI (Pharmacovigilance Programme of India): Managed by the Indian Pharmacopoeia Commission (IPC) under the Ministry of Health, PvPI collects, analyses, and acts on adverse drug reaction (ADR) reports from healthcare professionals and patients across India. As reported by The Times of India (June 5, 2026), the government has directed drug manufacturers to strengthen their ADR monitoring systems.
- State Drug Control Authorities: Each Indian state has its own drug control Directorate that conducts routine testing, enforces regulations locally, and coordinates with CDSCO on enforcement actions.
- National Pharmaceutical Regulatory Authority Coordination: Efforts are underway to integrate these bodies into a unified digital platform. According to the Drugs Controller General of India (DCGI), reported by Pharmabiz (August 3, 2026), CDSCO is launching the first phase of an end-to-end digital drug regulatory platform within 18 months.
📊 What Pharmacovigilance Means for Drug Safety
Pharmacovigilance (PV) is the science of detecting, assessing, understanding, and preventing adverse effects or any other drug-related problems. India’s PvPI programme, established in 2010, has steadily expanded its network of ADR monitoring centres. Key facts for buyers:
- ADR reporting infrastructure: PvPI operates through a network of Adverse Drug Reaction Monitoring Centres (AMCs) across government and private hospitals. These centres collect individual case safety reports (ICSRs) that feed into the national database.
- Signal detection: PvPI analyses aggregated ADR data to identify potential safety signals — patterns suggesting a drug may cause unexpected harm. When a signal is confirmed, regulatory action may follow, including label warnings, usage restrictions, or recalls.
- Recent regulatory actions: In June 2026, the IPC issued a warning about potential hyponatraemia risk with the blood pressure drug clonidine (Medical Dialogues, June 6, 2026). CDSCO has also mandated label warning updates on widely used antibiotics and thyroid drugs (The South First, February 24, 2026).
- Government direction: In June 2026, the central government directed drug manufacturers to strengthen their adverse event monitoring and reporting systems, signalling increased regulatory attention on post-market safety (Economic Times, June 4, 2026).
🔍 How CDSCO Enforces Quality After Approval
Pre-market approval is only the first step. CDSCO’s post-market quality enforcement is what buyers should pay closest attention to, because it reflects the regulator’s ongoing commitment to catching substandard products:
- Routine batch testing: Drug samples are collected from manufacturing facilities, wholesale distributors, and retail outlets across states. Samples are tested against Indian Pharmacopoeia (IP) standards at CDSCO-accredited and state drug control laboratories.
- NSQ classification: Batches that fail testing are classified as Not of Standard Quality (NSQ), spurious (counterfeit or deliberately adulterated), or misbranded. Each classification carries escalating regulatory consequences.
- Public notifications: CDSCO publishes NSQ alerts that name the affected product, manufacturer, batch number, and the specific quality parameter that failed. These are public records — any buyer can check whether a supplier’s products have appeared in NSQ notifications.
- Enforcement escalation: Consequences for substandard products include show cause notices, product recalls, manufacturing suspension, prosecution, and in severe cases, cancellation of the manufacturing licence.
✅ Checklist: What Buyers Should Verify Before Sourcing Indian Generic Medicines
Based on India’s current drug safety and quality framework, international buyers should verify the following before purchasing Indian generic medicines:
- CDSCO manufacturing approval (MA number): Confirm the specific drug, strength, and manufacturer holds a valid CDSCO manufacturing licence. This is the baseline regulatory requirement for any medicine sold in India.
- WHO-GMP / USFDA / EMA certification: For export-quality assurance, verify the manufacturing facility holds WHO-GMP certification, and where relevant, accreditation from the US FDA or European Medicines Agency. These certifications indicate that the facility meets international quality standards.
- Batch Certificate of Analysis (CoA): Request a valid CoA from an accredited laboratory for every batch being purchased. The CoA confirms the batch passed identity, purity, potency, and dissolution testing before release.
- NSQ history check: Search CDSCO NSQ notifications to see if the manufacturer or product has appeared in any quality alerts. A pattern of NSQ findings is a significant red flag.
- Manufacturer enforcement history: Check whether the manufacturer has appeared in USFDA import alerts, WHO prequalification delisting actions, or repeated CDSCO enforcement actions.
- Pharmacovigilance capability: For larger procurement programmes, consider whether the manufacturer has an active pharmacovigilance system for monitoring and reporting adverse events — increasingly important as India’s PV expectations grow.
- Product label and insert quality: Verify that the packaging, label, and patient information leaflet meet the specifications agreed upon and include necessary safety warnings.
- FDC ban status: If sourcing a fixed-dose combination product, confirm it has not been banned under the Drugs and Cosmetics Act. India has banned several FDCs over safety concerns.
⚠️ Red Flags International Buyers Should Watch For
When sourcing Indian generic medicines, be alert to these warning signs that may indicate quality or compliance risks:
- Prices significantly below market average: Extreme discounts can signal substandard quality, grey-market sourcing, or products diverted from regulated channels.
- Inability to provide documentation: A manufacturer or distributor that cannot produce CDSCO approval documentation, batch CoAs, or WHO-GMP certificates on request should be treated as unverified.
- “No-for-export” products being sold internationally: Products labelled for the Indian market only may not meet the regulatory standards of the destination country.
- No pharmacovigilance or adverse event reporting process: As India’s PV framework strengthens, the absence of any ADR monitoring arrangement is increasingly a gap worth questioning.
- Unverifiable contact information: Be cautious of suppliers who cannot provide a verifiable physical address, regulatory compliance documentation, or direct contact with a qualified representative.
🔗 Where to Find Verified Suppliers
For buyers seeking reliable pharmaceutical distributors and manufacturers, IMSDA’s verified member directory provides a starting point for identifying trusted suppliers. For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
Sources: CDSCO NSQ notifications (publicly available at cdsCO.gov.in); Pharmacovigilance Programme of India — IPC (ipc.gov.in); The Times of India, “Drug firms told to strengthen monitoring of medicine side effects,” June 5, 2026; Medical Dialogues, “IPC Warns of Potential Hyponatraemia Risk with Blood Pressure Drug Clonidine,” June 6, 2026; The Economic Times (pharma.economictimes.indiatimes.com), “Centre asks drugmakers to maintain system for adverse event reporting,” June 4, 2026; The South First, “CDSCO mandates warning updates on widely used antibiotic and thyroid drug,” February 24, 2026; Pharmabiz, “CDSCO to launch first phase of end-to-end digital drug regulatory platform within 18 months: DCGI,” August 3, 2026.
For more information, contact IMSDA at contact@indiamedicine.org.